Ranitidine Impairs Bone Healing and Implant Osseointegration in Rats' Tibiae.

J Oral Maxillofac Surg

Associate Professor, Faculty of Dentistry, McGill University, Montreal, Quebec, Canada; and Professor, College of Dental Medicine, Health Cluster, Qatar University, Doha, Qatar. Electronic address:

Published: November 2020

Purpose: Ranitidine has been found to have an impact on bone metabolism by suppressing osteoclastogenesis. We hypothesized that the use of ranitidine would impair bone healing and implant osseointegration. This study investigated the effect of postoperative administration of ranitidine on bone healing and osseointegration in rats.

Materials And Methods: Twenty-two Sprague-Dawley rats underwent surgery to create a unicortical bone defect in each tibia. A titanium implant was placed on the right tibial defect, whereas the contralateral defect was left unfilled. After surgery, the rats were randomly divided into 2 groups receiving a daily dose of ranitidine or saline solution for 14 days and then euthanized for assessment of bone healing and osseointegration using micro-computed tomography (CT) and histomorphometry.

Results: Micro-CT analysis of the bone defect showed a larger bone defect volume in the ranitidine group (0.82 ± 0.13 μL vs 0.66 ± 0.16 μL, P = .034), thinner cortical thickness (0.54 ± 0.07 mm vs 0.63 ± 0.11 mm, P = .026), and less bone regeneration at the defect site (40% ± 12% vs 57% ± 11%, P = .003). Implant-site micro-CT analysis showed less osseointegration in the ranitidine group (34.1% ± 2.7% vs 43.5% ± 2.1%, P = .014), and implant-site histologic analysis showed less medullary (P = .021), cortical (P = .001), and total (P = .003) bone-implant contact and less peri-implant bone volume-tissue volume (P = .002) in the ranitidine group. Histologic analysis for osteoclastic activity showed a lower number of osteoclasts in the ranitidine group (4.8 ± 2.4 mm vs 9.1 ± 2.1 mm, P = .026).

Conclusions: The postoperative use of ranitidine impaired bone healing and osseointegration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.joms.2020.06.027DOI Listing

Publication Analysis

Top Keywords

bone healing
20
ranitidine group
16
healing osseointegration
12
bone defect
12
bone
11
ranitidine
10
healing implant
8
implant osseointegration
8
micro-ct analysis
8
histologic analysis
8

Similar Publications

Total hip arthroplasty in hip tuberculosis: a systematic review.

BMC Musculoskelet Disord

January 2025

Department of Joint Surgery, The Second Hospital of Jilin University, Changchun, 130,000, Jilin Province, China.

Objectives: Tuberculosis of the hip joint is a common form of bone tuberculosis that can cause severe joint destruction and affect quality of life. Total hip arthroplasty (THA) is an important way to treat hip joint-related diseases. In recent years, THA has been applied to treat tuberculosis of the hip joint and has achieved certain results.

View Article and Find Full Text PDF

Background: Osteoporosis fracture is a common and most serious complication of osteoporosis.

Hypothesis: This study sought to assess the level, the diagnostic potential, and the effect of circulating miR-4534 in osteoporotic fractures.

Methods: GSE74209 and GSE93883 were analyzed using GEO2R online tool for differentially expressed microRNAs in osteoporotic fractures.

View Article and Find Full Text PDF

The journey of bone repair is a lengthy process. Traditionally, oral or topical medications have been employed to facilitate healing, approaches that are not only costly but may also lead to adverse effects such as gastrointestinal damage. With advancements in electrophysiology, the significance of bioelectric activity in tissue repair has become increasingly prominent, thereby enhancing the focus on research into electroacupuncture (EA) for bone repair.

View Article and Find Full Text PDF

Background: Fracture disrupts the integrity and continuity of the bone, leading to symptoms such as pain, tenderness, swelling, and bruising. Rhizoma Musae is a medicinal material frequently utilized in the Miao ethnic region of Guizhou Province, China. However, its specific mechanism of action in treating fractures remains unknown.

View Article and Find Full Text PDF

Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.

J Bone Oncol

February 2025

Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.

Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!